Total medical devices industry venture financing deals worth $733.7m were announced in Asia-Pacific in May 2021, led by $200m venture financing of Esco Micro, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 79.9% over the previous month of $407.76m and a rise of 109.7% when compared with the last 12-month average of $349.95m.
Asia-Pacific held a 24.29% share of the global medical devices industry venture financing deal value that totalled $3.02bn in May 2021. With a 15.56% share and deals worth $469.95m, China was the top country in Asia-Pacific’s venture financing deal value across medical devices industry.
In terms of venture financing deal activity, Asia-Pacific recorded 25 deals during May 2021, marking a decrease of 7.41% over the previous month and a drop of 10.71% over the 12-month average. China recorded 18 deals during the month.
Asia-Pacific medical devices industry venture financing deals in May 2021: Top deals
The top five medical devices industry venture financing deals accounted for 67.9% of the overall value during May 2021.
The combined value of the top five medical devices venture financing deals stood at $498.15m, against the overall value of $733.7m recorded for the month.
The top five medical devices industry venture financing deals of May 2021 tracked by GlobalData were:
1) China Investment, EDBI, Novo Holdings and Vivo Capital’s $200m venture financing of Esco Micro
2) The $93.34m venture financing of Kailian Medical Technology by Beijing Fuhai Schwab Investment Consulting, Eight Roads Ventures, Qiandao Investment Holding Group and Shenzhen Oriental Fortune Capital
3) Beijing Junlian Capital Management, CPE Yuanfeng, Eli Lilly Asia Fund (LAV), Hillhouse Ventures, Qiming Venture Capital, Sanzheng Health Investment, Taifu Capital, Temasek Holdings (HK) and Yunfeng Fund L.P’s $77.78m venture financing of Jiangsu Hailai Xinchuang Medical Technology
4) The $64.89m venture financing of SShanghai Diluo Medical Equipment by Bohang Capital, CPE Funds Management, Insight Capital and Legend Capital
5) Fosun Pharma, Gao Ling (Tianjin) Venture Capital, LYFE Capital and SoftBank China Capital’ venture financing of Hangzhou Jianjia Robot for $62.15m.